Recent progress in therapeutic applications of chalcones

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 10, 2011, Pages 1575-1596

  Katsori, Anna Maria ^a   Hadjipavlou Litina, Dimitra ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

, unsaturated ketone; 1,3 diphenyl 2 propenone; Anti bacterial; Anti cancer; Anti inflammatory; Chalcone

Indexed keywords

1 ADAMANTYL CHALCONE DERIVATIVE; 3 CYANO 4,6 DIPHENYLPYRIDINE DERIVATIVE; 4,6 DIPHENYLPYRIMIDINE DERIVATIVE; 5,6,7,8 TETRAHYDROBENZO[1]THIENO[2,3 D]PYRIMIDINE DERIVATIVE; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ANTIBIOTIC AGENT; ANTILEISHMANIAL AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; CHALCONE; CHALCONE DERIVATIVE; DOXORUBICIN; DROLOXIFENE; FLAVONOID; GENISTEIN; IDOXIFENE; INDOMETACIN; KOJIC ACID; LICOCHALCONE A; MATRIX METALLOPROTEINASE INHIBITOR; MIPROXIFENE; PACLITAXEL; RALOXIFENE; SULFIDE; SULFONE; SULFOXIDE; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; CHRONIC MYELOID LEUKEMIA; COMEDO; CYTOTOXICITY; DRUG SYNTHESIS; EAR DISEASE; EAR EDEMA; EDEMA; ENZYME INHIBITION; ESCHERICHIA COLI; EXTRACELLULAR MATRIX; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROSTATE CANCER; REVIEW; STAPHYLOCOCCUS INTERMEDIUS; TRYPANOSOMA CRUZI;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CHALCONES; DRUG DESIGN; HUMANS; INFLAMMATION; NEOPLASMS; PATENTS AS TOPIC;

EID: 80053045924     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.596529     Document Type: Review

References (83)

1. Ni L, Meng CQ, Sikorski JA. Recent advances in therapeutic chalcones. Expert Opin Ther Pat 2004;14(12):1669-91 (Pubitemid 39625100)
2. Damazio RG, Zanatta AP, Cazarolli LH, et al. Antihyperglycemic activity of naphthylchalcones. Eur J Med Chem 2010;45(4):1332-7
3. Fuhrmann GF, Dernedde S, Frenking G. Phloretin keto-enol tautomerism and inhibition of glucose transport in human erythrocytes (including effects of phloretin on anion transport). BBA Biomembranes 1992;1110(1):105-11
4. Calliste CA, Le Bail JC, Trouillas P, et al. Chalcones: structural requirements for antioxidant, estrogenic and antiproliferative activities. Anticancer Res 2001;21(6A):3949-56 (Pubitemid 34229269)
5. Kobori M, Shinmoto H, Tsushida T, Shinohara K. Phloretin-induced apoptosis in B16 melanoma 4A5 cells by inhibition of glucose transmembrane transport. Cancer Lett 1997;119(2):207-12 (Pubitemid 27478105)
6. Kim M-Y, Park B-Y, Kim K-M, et al. inventors; Angiolab Inc., assignee. Composition containing chalcone patent. US7572831; 2009
7. Kontogiorgis CA, Papaioannou P, Hadjipavlou-Litina DJ. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Curr Med Chem 2005;12(3):339-55 (Pubitemid 40305624)
8. Cheng M, De B, Pikul S, et al. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. J Med Chem 2000;43(3):369-80 (Pubitemid 30102077)
9. Skiles JW, Monovich LG, Jeng AY. Matrix metalloproteinase inhibitors for treatment of cancer. Chapter 15. Annu Rep Med Chem Academic Press; United Kingdom; 2000. p. 167-76
10. Chapman KT, Kopka IE, Durette PL, et al. Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides. J Med Chem 1993;36(26):4293-301 (Pubitemid 24037940)
11. Grant DS, Tashiro K-I, Segui-Real B, et al. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 1989;58(5):933-43 (Pubitemid 19227901)
12. Kruger EA, Figg WD. Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay. Clin Cancer Res 2001;7(7):1867-72 (Pubitemid 32994819)
13. Park KH, Kim JH, Seo WD, et al. inventors; Industry-Academic Cooperation Foundation Gyeongsang National University, assignee Novel chalcone derivatives, pharmaceutically acceptable salt, method for preparation and uses thereof patent. WO114532; 2007
14. Moremen K, Trimble RB, Herscovics A. Glycosidases of the asparagine-linked oligosaccharide processing pathway. Glycobiology 1994;4(2):113-25 (Pubitemid 24147887)
15. Bertozzi CR, Kiessling LL. Chemical glycobiology. Science 2001;291(5512):2357-64 (Pubitemid 32231790)
16. Fernandes B, Sagman U, Auger M, et al. beta1-6 Branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 1991;51(2):718-23
17. Liu M, Wilairat P, Go M-L. Antimalarial alkoxylated and hydroxylated chalones: structure-activity relationship analysis. J Med Chem 2001;44(25):4443-52 (Pubitemid 33131668)
18. Arockia Babu M, Shakya N, Prathipati P, et al. Development of 3D-QSAR models for 5-Lipoxygenase antagonists: chalcones. Bioorg Med Chem 2002;10(12):4035-41 (Pubitemid 36164703)
19. Barfod L, Kemp K, Hansen M, Kharazmi A. Chalcones from Chinese liquorice inhibit proliferation of T cells and production of cytokines. Int Immunopharmacol 2002;2(4):545-55 (Pubitemid 34169749)
20. Rojas J, Paya M, Dominguez JN, Luisa Ferrandiz M. The synthesis and effect of fluorinated chalcone derivatives on nitric oxide production. Bioorg Med Chem Lett 2002;12(15):1951-4 (Pubitemid 34756456)
21. Kumar SK, Hager E, Pettit C, et al. Design, synthesis, and evaluation of novel Boronic-Chalcone derivatives as antitumor agents. J Med Chem 2003;46(14):2813-15 (Pubitemid 36775907)
22. Navarini AL, Chiaradia LD, Mascarello A, et al. Hydroxychalcones induce apoptosis in B16-F10 melanoma cells via GSH and ATP depletion. Eur J Med Chem 2009;44(4):1630-7
23. Artico M, Di Santo R, Costi R, et al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. J Med Chem 1998;41(21):3948-60 (Pubitemid 28483472)
24. Mascarello A, Chiaradia LD, Vernal J, et al. Inhibition of Mycobacterium tuberculosis tyrosine phosphatase PtpA by synthetic chalcones: kinetics, molecular modeling, toxicity and effect on growth. Bioorg Med Chem 2010;18(11):3783-9
25. Nerya O, Vaya J, Musa R, et al. Glabrene and isoliquiritigenin as tyrosinase inhibitors from licorice roots. J Agric Food Chem 2003;51(5):1201-7
26. Maeda K, Fukuda M. In vitro effectiveness of several whitening cosmetic components in human melanocytes. J Soc Cosmet Chem 1991;42:361-8
27. Nielsen SF. inventor Lica Pharmaceuticals A/S, assignee Quaternary Amino-Function Chalcones patent. WO042467; 2005
28. Tsukiyama R-I, Katsura H, Tokuriki N, Kobayashi M. Antibacterial activity of licochalcone a against spore-forming bacteria. Antimicrob Agents Chemother 2002;46(5):1226-30 (Pubitemid 34415295)
29. Hammond GB, Aponte JC, Gilman RH, et al. inventors; University of Louisville Research Foundation Inc, Universidad Peruma Cayetano Heredia, Institut de Recherche Pour le Developpement, The Johns Hopkins University, assignee Compounds, their syntheses, and their uses patent. WO019861; 2010
30. Boeck P, Bandeira Falcao CA, Leal PC, et al. Synthesis of chalcone analogues with increased antileishmanial activity. Bioorg Med Chem 2006;14(5):1538-45 (Pubitemid 43120289)
31. Blackwell HE, Bowman MD, ONeill JC, Stringer JR. inventors; Wisconsin Alumni Research Foundation, assignee Antibacterial agents and related screening methods using small molecule macroarrays patent. US0009528; 2008
32. Hilpert K, Volkmer-Engert R, Walter T, Hancock REW. High-throughput generation of small antibacterial peptides with improved activity. Nat Biotech 2005;23(8):1008-12 (Pubitemid 41114036)
33. Nielsen SF, Boesen T, Larsen M, et al. Antibacterial chalcones- bioisosteric replacement of the 4′-hydroxy group. Bioorg Med Chem 2004;12(11):3047-54 (Pubitemid 38622138)
34. Nielsen SF, Larsen M, Boesen T, et al. Cationic chalcone antibiotics. Design, synthesis, and mechanism of Action. J Med Chem 2005;48(7):2667-77 (Pubitemid 40516456)
35. Bowman MD, Jacobson MM, Pujanauski BG, Blackwell HE. Efficient synthesis of small molecule macroarrays: optimization of the macroarray synthesis platform and examination of microwave and conventional heating methods. Tetrahedron 2006;62(19):4715-27
36. Boddupalli S, Mahmood K, Saliou C. inventors; Johnson & Johnson Consumer Companies, Inc., Galileo Pharmaceuticals, Inc., assignee Use of chalcones for the treatment of viral disorders patent. WO127539; 2006
37. Abou-Karam M, Shier WT. A simplified plaque reduction assay for antiviral agents from plants. Demonstration of frequent occurrence of antiviral activity in higher plants. J Nat Prod 1990;53(2):340-4 (Pubitemid 20202672)
38. Huang R, Jian J, Lin X, et al. inventors; Peop. Rep. China, assignee Preparation of Chinese medicine Yulansan chalcone monomer and use thereof patent. CN101463022; 2009
39. Shindo K, Kitazawa H, Kitagawa M, Sogabe A. inventors; Toyobo Co. Ltd, assignee Antioxidants containing chalcone glycosides patent. JP247839; 2008
40. Rommens C. inventor J.R. Simplot Co., assignee High level antioxidant-containing food patent. WO005474; 2008
41. Konieczny M, Skladanowski A, Lemke K, Pieczykolan J. inventors; Adamed Sp. z o.o., assignee Novel chalcone derivatives with cytotoxic activity patent. WO009826; 2011
42. Bigi F, Casiraghi G, Casnati G, et al. Unusual Friedel-Crafts reactions, IX. One-step ortho-acylation of phenols with [alpha],[beta]-unsaturated acyl chlorides. Synthesis of 2′-hydroxychalcones and sorbicillin analogues. Tetrahedron 1984;40(20):4081-4
43. Romeo A, Bargellini G. Flavonic compounds with the methylenedioxy group in the chromone nucleus. The mechanism of formation of o-hydroxychalcones and flavanones. Ann Chim 1952;42:361-9
44. Winter E, Chiaradia LD, de Cordova CA, et al. Naphthylchalcones induce apoptosis and caspase activation in a leukemia cell line: The relationship between mitochondrial damage, oxidative stress, and cell death. Bioorg Med Chem 2010;18(22):8026-34
45. Pedrini FS, Chiaradia LD, Licinio MA, et al. Induction of apoptosis and cell cycle arrest in L-1210 murine lymphoblastic leukaemia cells by (2E)-3-(2-naphthyl)-1-(3′-methoxy-4′- hydroxy-phenyl)-2-propen-1- one. J Pharm Pharmacol 2010;62(9):1128-36
46. Boumendjel A, Ronot X, Boutonnat J. Chalcones derivatives acting as cell cycle blockers: potential anti cancer drugs? Curr Drug Targets 2009;10(4):363-71
47. Katsori AM, Hadjipavlou-Litina D. Chalcones in cancer: understanding their role in terms of QSAR. Curr Med Chem 2009;16(9):1062-81
48. Ducki S. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly. Anticancer Agents Med Chem 2009;9(3):336-47
49. Batovska DI, Todorova IT. Trends in utilization of the pharmacological potential of chalcones. Curr Clin Pharmacol 2010;5(1):1-29
50. Konieczny MT, Konieczny W, Okabe S, et al. Synthesis and cytostatic activity of 4,7-dihydroxythioaurone derivatives. Effect of B ring substitution on the activity. Chem Pharm Bull (Tokyo) 2006;54(3):350-3
51. Reddy EP, Reddy MVR. inventors; Temple University-Of the Commonwealth System of Higher Education, assignee Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof patent. WO076270; 2008
52. Boumendjel A, Dumontet C, Blanc M, Mariotte AM. inventors; Universite Claude Bernard Lyon 1, Universite Joseph Fourier Grenoble I. assignee Novel chalcone derivatives with antimitotic activity patent. FR2896245; 2007
53. Anderson GL, Kaimari TA-R. inventors; USA, assignee 1-adamantyl chalcones for the treatment of proliferative disorders patent. US6864264; 2005
54. Hibbs DE, Salam NK, Roubin R, et al. inventors; The University of Sydney, assignee PPAR agonists patent. WO026658; 2009
55. Yamazaki Y, Kono Y. inventors; National Institute of Advanced Industrial Science & Technology, assignee Inflammatory interleukin production inhibitor patent. JP120720; 2008
56. Yamazaki Y, Kono Y. inventors; National Institute of Advanced Industrial Science & Technology, assignee TNF-alpha formation inhibitors patent. JP106014; 2008
57. Yamazaki Y, Kono Y. inventors; National Institute of Advanced Industrial Science & Technology, assignee TNF-alpha formation inhibitors patent. JP106013; 2008
58. Wong N, Tucker J, McCaffrey DR. inventors; Resverlogix Corp., assignee Treatment of diseases associated with the egr-1 enhancer element patent. US0099826; 2007
59. Nimura Y. inventor Japan, assignee Pinocembrin chalcones as inhibitors of producing inflammatory cytokines, and food preparations, cosmetics, and anti-inflammatory agents containing them patent. JP204444; 2007
60. Ito Y, Miyake Y, Okada K. inventors Maruzen Pharmaceuticals Co. Ltd., assignee. Reduced chalcone compound and method of producing the same, reduced product of fat-soluble licorice root extract and method of producing the same, cyclooxygenase-2 activity inhibitor, whitening agent, antiinflammatory agent and cosmetic patent. WO052330; 2007
61. Akihisa T, Yasukawa T, Ukiya M, Hasegawa D. inventors; Nihon University, assignee Anti-inflammatory patent. JP001898; 2007
62. Furuhashi I, Inoue H, Iwata S, Sato S. inventors; Minophagen Pharmaceutical Co. Ltd., assignee Prostaglandin production and anti-inflammatory inhibitors patent. JP6282639; 2006
63. Futaki N, Takahashi S, Yokoyama M, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47(1):55-9 (Pubitemid 24053843)
64. Furuhashi I, Iwata S, Sato T, et al. Inhibition by licochalcone A, a novel flavonoid isolated from liquorice root, of IL-1beta-induced PGE2 production in human skin fibroblasts. J Pharm Pharmacol 2005;57(12):1661-6 (Pubitemid 41752280)
65. Redda K, Mills CJ, Mateeva N. inventors; USA, assignee Synthetic flavonoids and pharmaceutical compositions and therapeutic methods of treatment of cancer and other pathologies patent. US312407; 2009
66. Mills CJ, Mateeva NN, Redda KK. Synthesis of novel substituted flavonoids. J Heterocycl Chem 2006;43(1):59-64 (Pubitemid 43108069)
67. Kamal A, Rajendra PB, Reddy AM. inventors; Council of Scientific & Industrial Research., assignee Chalcone Linked Pyrrolo [ 2,1-c ] [1, 4] Benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof patent. WO109986; 2009
68. Cipolla L, Araujo AC, Airoldi C, Bini D. Pyrrolo[2,1-c][1,4] benzodiazepine as a scaffold for the design and synthesis of anti-tumour drugs. Anticancer Agents Med Chem 2009;9(1):1-31
69. Kamal A, Ramesh G, Laxman N, et al. Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient dna binding ability and potent antitumor activity. J Med Chem 2002;45(21):4679-88
70. Kamal A, Shankaraiah N, Prabhakar S, et al. Solid-phase synthesis of new pyrrolobenzodiazepine-chalcone conjugates: DNA-binding affinity and anticancer activity. Bioorg Med Chem Lett 2008;18(7):2434-9 (Pubitemid 351444875)
71. Kamal A, Srinivas O, Ramulu P, et al. Synthesis of novel C2 and C2-C8 linked pyrrolo[2,1-c][1,4]benzodiazepinenaphthalimide hybrids as DNA-binding agents. Bioorg Med Chem Lett 2003;13(20):3577-81 (Pubitemid 37141433)
72. Kamal A, Rao MV, Laxman N, et al. Recent Developments in design, synthesis and structure activity relationship studies of Pyrrolo[2,1-c][1,4] benzodiazepines as DNA-interactive antitumor antibiotics. Curr Med Chem Anticancer Agents 2002;33(43):215-74
73. Bachmann E, Weber E, Zbinden G. Effects of seven anthracyclin antibiotics on electrocardiogram and mitochondrial function of rat hearts. Agents Actions 1975;5(4):383-93
74. Park KH, Lee JW, Ryu YB, et al. inventors; Seoul Nationaluniversity Industry Foundation, Industry-Academic Cooperation Foundation Gyeongsang National University, assignee Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds patent. WO069608; 2008
75. Lee SA, Lee SY, Cho IH, et al. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest 2008;118(4):1354-66
76. Muller-Pillasch F, Wallrapp C, Lacher U, et al. Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene 1998;208(1):25-30 (Pubitemid 28085272)
77. Lee S-Y, Kim YT, Lee M-S, et al. Focal adhesion and actin organization by a cross-talk of TM4SF5 with integrin [alpha]2 are regulated by serum treatment. Exp Cell Res 2006;312(16):2983-99 (Pubitemid 44292657)
78. Lee S-A, Ryu HW, Kim YM, et al. Blockade of four-transmembrane L6 family member 5 (TM4SF5)- mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 2009;49(4):1316-25
79. Suarez JAQ, Peseke K, Molina RR. inventors; Riemser Arzneimittel AG, assignee Substituted acetophenonederivatives patent. EP1764363; 2007
80. Rose SD, Hartman RF. inventors; Arizona Biomedical Research Commission, assignee Modified chalcone compounds as antimitotic agents patent. US0265317; 2007
81. Edwards ML, Stemerick DM, Sunkara PS. Chalcones: a new class of antimitotic agents. J Med Chem 1990;33(7):1948-54 (Pubitemid 20228984)
82. Shan B, Medina JC, Santha E, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci USA 1999;96(10):5686-91 (Pubitemid 29234679)
83. Wei X, Zhang F, Zhu X. inventors; South China Botanical Garden, Chinese Academy of Sciences, Peop. Rep. China, Cancer Center of Sun Yat-Sen University, assignee Charles ketone oxime and its composition, preparation method and uses patent. CN1807405; 2006